Combined Cardiac Damage Staging by Echocardiography and Cardiac Catheterization in Patients With Clinically Significant Aortic Stenosis

Belmonte, Marta; Paolisso, Pasquale; Bertolone, Dario Tino; Viscusi, Michele Mattia; Gallinoro, Emanuele; de Oliveira, Elayne Kelen; Shumkova, Monika; Beles, Monika; Esposito, Giuseppe; Addeo, Lucio; Botti, Giulia; Moya, Ana; Leone, Attilio; Wyffels, Eric; De Bruyne, Bernard; van Camp, Guy; Bartunek, Joseph; Barbato, Emanuele; Penicka, Martin; Vanderheyden, Marc

doi:10.1016/j.cjca.2023.11.010

Cited by 7 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to patients with HG AS, those with LF-LG AS have a markedly poorer prognosis with mortality rates of 30-50% at 2 years despite aortic valve replacement (AVR), being a challenging sub-group for both diagnosis and therapeutic management. [3][4][5] The pathophysiology of LF-LG AS and mechanisms responsible for left ventricular (LV) dysfunction are poorly understood. Compared to HG AS, patients with LF-LG AS show more extensive myocardial fibrosis on cardiac magnetic resonance (CMR).…”

Section: Introductionmentioning

confidence: 99%

Myocardial sodium–glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: The BIO‐AS study

Scisciola,

Paolisso,

Belmonte

et al. 2024

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

AimCardiac remodelling plays a major role in the prognosis of patients with aortic stenosis (AS) and could impact the benefits of aortic valve replacement. Our study aimed to evaluate the expression of sodium–glucose cotransporter 2 (SGLT2) gene and protein in patients with severe AS stratified in high gradient (HG) and low flow‐low gradient (LF‐LG) AS and its association with cardiac functional impairments.Methods and resultsGene expression and protein levels of main biomarkers of cardiac fibrosis (galectin‐3, sST2, serpin‐4, procollagen type I amino‐terminal peptide, procollagen type I carboxy‐terminal propeptide, collagen, transforming growth factor [TGF]‐β), inflammation (growth differentiation factor‐15, interleukin‐6, nuclear factor‐κB [NF‐κB]), oxidative stress (superoxide dismutase 1 [SOD1] and 2 [SOD2]), and cardiac metabolism (sodium–hydrogen exchanger, peroxisome proliferator‐activated receptor [PPAR]‐α, PPAR‐γ, glucose transporter 1 [GLUT1] and 4 [GLUT4]) were evaluated in blood samples and heart biopsies of 45 patients with AS. Our study showed SGLT2 gene and protein hyper‐expression in patients with LF‐LG AS, compared to controls and HG AS (p < 0.05). These differences remained significant even after adjusting for age, gender, body mass index, history of diabetes mellitus, arterial hypertension, and coronary artery disease. SGLT2 gene expression was positively correlated with: (i) TGF‐β (r = 0.72, p < 0.001) and collagen (r = 0.73, p < 0.001) as markers of fibrosis; (ii) NF‐κB (r = 0.36, p < 0.01) and myocardial interleukin‐6 (r = 0.68, p < 0.001) as markers of inflammation: (iii) SOD2 (r = −0.38, p < 0.006) as a marker of oxidative stress; (iv) GLUT4 (r = 0.33, p < 0.02) and PPAR‐α (r = 0.36, p < 0.01) as markers of cardiac metabolism.ConclusionIn patients with LF‐LG AS, SGLT2 gene and protein were hyper‐expressed in cardiomyocytes and associated with myocardial fibrosis, inflammation, and oxidative stress.

show abstract

Section: Introductionmentioning

confidence: 99%